论文部分内容阅读
目的：评价普罗布考片应用于高脂血症患者的有效性和安全性。方法：３３例高脂血症患者连续服用普罗布考片８周，ｂｉｄ，５００ｍｇ／次。用药后４周及８周测定血清总胆固醇（ＴＣ）、高密度脂蛋白（ＨＤＬＣ）、甘油三酯（ＴＧ），并根据公式推算出低密度脂蛋白（ＬＤＬＣ）。结果：服用普罗布考片４周和８周后，患者ＴＣ下降２６．２％和２５．０％（Ｐ均＜０．００１），ＬＤＬＣ下降３２．１％和３４．２％（Ｐ均＜０．００１），ＨＤＬＣ下降１３．９％（Ｐ＜０．０５）和６．４％（Ｐ＞０．０５）。对伴有高甘油三酯血症的患者而言，ＴＧ分别下降７．７％和１１．８％（Ｐ均＞０．０５）。在本研究中，只有１名患者因为腹泻而退出研究，没有发现其他严重的不良反应。结论：普罗布考片可以安全、有效地降低高胆固醇血症患者的ＴＣ，ＬＤＬＣ和ＨＤＬＣ。
Objective: To evaluate the effectiveness and safety of probucol tablets in patients with hyperlipidemia. Methods: 33 cases of hyperlipidemia patients taking probucol tablets for 8 weeks, bid, 500mg / time. Serum total cholesterol (TC), high-density lipoprotein (HDL-C) and triglyceride (TG) were measured at 4 weeks and 8 weeks after treatment and LDL-C was calculated according to the formula. Results: After taking probucol tablets for 4 weeks and 8 weeks, TC decreased by 26.2% and 25.0% (P <0.001), LDL-C decreased by 32.1% and 34.2% (P All <0.001), HDL-C decreased by 13.9% (P <0.05) and 6.4% (P> 0.05). For patients with hypertriglyceridemia, TG decreased by 7.7% and 11.8%, respectively (all P> 0.05). In this study, only one patient withdrew from the study because of diarrhea and found no other serious adverse reactions. Conclusions: Probucol tablets can reduce TC, LDLC and HDLC in patients with hypercholesterolemia safely and effectively.